API | pemafibrate

pemafibrate Report issue

Small molecule Experimental

AACT

Active Ingredient History

NOW

Pemafibrate, sold under the brand namd Parmodia, is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It is developed and marketed by Kowa Pharmaceuticals. ^Wikipedia

Chemistry

SMILES: CC[C@@H](Oc1cccc(CN(CCCOc2ccc(OC)cc2)c2nc3ccccc3o2)c1)C(=O)O
InChIKey: ZHKNLJLMDFQVHJ-RUZDIDTESA-N
Mol. Mass: 490.56
ALogP: 5.55 Partition coefficient
ChEMBL Molecule:
pemafibrate

More Chemistry

Pharmacology

Mechanisms of Action:
- Peroxisome proliferator-activated receptor alpha (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Oral
Pro Drug: No

pemafibrate | sk-1405

Organizations (5)

Research & Development (5)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (8)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (8)

Diabetic Retinopathy (Phase 3)

Dyslipidemias (Phase 3)

Healthy Volunteers (Phase 1)

Hyperlipidemias (Phase 3)

Lipoproteins (Phase 2)

Macular Edema (Phase 3)

Pruritus (Phase 2)

Renal Insufficiency (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 11
# of Trial Organizations: 5

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue